186 related articles for article (PubMed ID: 38411094)
21. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
22. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
23. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
Kawashima S; Togashi Y
Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
[TBL] [Abstract][Full Text] [Related]
24. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
25. Drug-drug conjugates self-assembled nanomedicines triggered photo-/immuno- therapy for synergistic cancer treatments.
Qu H; Li L; Chen H; Tang M; Cheng W; Lin TY; Li L; Li B; Xue X
J Control Release; 2023 Nov; 363():361-375. PubMed ID: 37751826
[TBL] [Abstract][Full Text] [Related]
26. Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.
Zhang H; Tang WL; Kheirolomoom A; Fite BZ; Wu B; Lau K; Baikoghli M; Raie MN; Tumbale SK; Foiret J; Ingham ES; Mahakian LM; Tam SM; Cheng RH; Borowsky AD; Ferrara KW
J Control Release; 2021 Feb; 330():1080-1094. PubMed ID: 33189786
[TBL] [Abstract][Full Text] [Related]
27. Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.
Su L; Pan W; Li X; Zhou X; Ma X; Min Y
Acta Biomater; 2023 Mar; 158():698-707. PubMed ID: 36563773
[TBL] [Abstract][Full Text] [Related]
28. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC; Dillon MT; Nenclares P; Grove L; Soliman H; Leslie I; Northcote D; Bozhanova G; Crespo-Rodriguez E; Baldock H; Whittock H; Baker G; Kyula J; Guevara J; Melcher AA; Harper J; Ghadially H; Smith S; Pedersen M; McLaughlin M; Harrington KJ
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314434
[TBL] [Abstract][Full Text] [Related]
29. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
30. Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation.
Chen SF; Kau M; Wang YC; Chen MH; Tung FI; Chen MH; Liu TY
Int J Nanomedicine; 2023; 18():7677-7693. PubMed ID: 38111846
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
[TBL] [Abstract][Full Text] [Related]
32. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
33. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
[TBL] [Abstract][Full Text] [Related]
34. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
[TBL] [Abstract][Full Text] [Related]
35. A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy.
Phuengkham H; Song C; Lim YT
Adv Mater; 2019 Oct; 31(42):e1903242. PubMed ID: 31490604
[TBL] [Abstract][Full Text] [Related]
36. Surface-Functionalized Modified Copper Sulfide Nanoparticles Enhance Checkpoint Blockade Tumor Immunotherapy by Photothermal Therapy and Antigen Capturing.
Wang R; He Z; Cai P; Zhao Y; Gao L; Yang W; Zhao Y; Gao X; Gao F
ACS Appl Mater Interfaces; 2019 Apr; 11(15):13964-13972. PubMed ID: 30912920
[TBL] [Abstract][Full Text] [Related]
37. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
Lin X; Li F; Guan J; Wang X; Yao C; Zeng Y; Liu X
ACS Nano; 2023 Aug; 17(15):14494-14507. PubMed ID: 37485850
[TBL] [Abstract][Full Text] [Related]
38. Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy.
Cao Y; Ding S; Zeng L; Miao J; Wang K; Chen G; Li C; Zhou J; Bian XW; Tian G
ACS Appl Mater Interfaces; 2021 Nov; 13(45):53504-53518. PubMed ID: 34704726
[TBL] [Abstract][Full Text] [Related]
39. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance.
Peng J; Yin X; Yun W; Meng X; Huang Z
Cancer Lett; 2023 Apr; 559():216108. PubMed ID: 36863506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]